Cargando…

LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures

Pediatric low-grade glioma (pLGG), the most common brain tumors in children, are driven by alterations in the MAPK pathway. Several clinical trials have shown the potential for MAPK inhibitor (MAPKi) treatment in pLGG. However, the range of response to MAPKi is heterogeneous, even between tumors sha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sigaud, Romain, Heß, Caroline, Hielscher, Thomas, Winkler, Nadine, Selt, Florian, Kocher, Daniela, Nonnenbroich, Leo, Usta, Diren, Sommerkamp, Alex, Büdenbender, Isabel, Capper, David, Thomale, Ulrich W, Driever, Pablo Hernáiz, le Simon, Michè, Koch, Arend, Jabado, Nada, Andrade, Augusto F, van Meeteren, Netteke Schouten-, Hoving, Eelco, van Tilburg, Cornelis M, Pfister, Stefan M, Witt, Olaf, Jones, David T W, Milde, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Low Grade Glioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165112/ http://dx.doi.org/10.1093/neuonc/noac079.340

Ejemplares similares

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2020)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY
por: Usta, Diren, et al.
Publicado: (2020)

LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients
por: Hardin, Emily C, et al.
Publicado: (2022)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-02. DRUG-CLASS SPECIFIC GENE-BASED MAPK SENSITIVITY SCORES (MSS) PREDICT SENSITIVITY TO MAPK INHIBITORS AND IDENTIFY IMMUNE INFILTRATION AS PUTATIVE TARGET IN PEDIATRIC LOW-GRADE GLIOMAS
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA
por: Selt, Florian, et al.
Publicado: (2021)

LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma
por: Kocher, Daniela, et al.
Publicado: (2022)

LGG-09. SENOLYTIC AGENT NAVITOCLAX TARGETS VINBLASTINE- AND MAPK INHIBITORS-INDUCED SENESCENT TUMOUR CELLS IN PAEDIATRIC LOW GRADE GLIOMAS
por: Guiho, Romain, et al.
Publicado: (2021)

LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-56. Surgical management of pre-chiasmatic intraorbital optic nerve gliomas in children after loss of visual function – Resection from bulbus to chiasm
por: Zipfel, Julian, et al.
Publicado: (2022)

LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology
por: Boisvert, Michelle, et al.
Publicado: (2022)

LGG-11. INSTITUTIONAL EXPERIENCE OF BRAF TARGETING THERAPY
por: Lola, Gino Bardi, et al.
Publicado: (2020)

LGG-06. COMPREHENSIVE GENOMIC CHARACTERIZATION AND INTEGRATED CLINICAL ANALYSIS OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1
por: Fisher, Michael, et al.
Publicado: (2021)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)

LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS
por: Condurat, Alexandra-Larisa, et al.
Publicado: (2020)

LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01
por: Perreault, Sébastien, et al.
Publicado: (2020)

LGG-29. TREATMENT FOR RECURRENT OPTIC PATHWAY PILOCYTIC ASTROCYTOMA
por: Nonaka, Masahiro, et al.
Publicado: (2020)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION
por: Uchida, Hiroyuki, et al.
Publicado: (2020)

LGG-57. SIGNALLING MECHANISMS IN PAEDIATRIC LOW-GRADE GLIOMA
por: Patel, Ankit, et al.
Publicado: (2020)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

LGG-46. MOLECULAR CHARACTERIZATION OF HEMISPHERIC LOW-GRADE GLIOMAS IN CHILDREN
por: Mišove, Adéla, et al.
Publicado: (2020)

LGG-13. THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS
por: Bennett, Julie, et al.
Publicado: (2020)

LGG-42. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy
por: Chan, Priya, et al.
Publicado: (2022)

LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults
por: Bennett, Julie, et al.
Publicado: (2022)

LGG-37. Long-term Outcome, Visual Morbidity and Prognostic Factors in Infants and Young Children with Optic Pathway Glioma from the Great Ormond Street Hospital (GOSH) LGG - Cohort
por: Picariello, Stefania, et al.
Publicado: (2022)

LGG-33. ISOMORPHIC DIFFUSE GLIOMA HAS RECURRENT GENE FUSIONS OF MYBL1 OR MYB AND CAN BE DISTINGUISHED FROM OTHER MYB/MYBL1 ALTERED GLIOMAS BASED ON A DISTINCT MORPHOLOGY AND DNA METHYLATION PROFILE
por: Wefers, Annika K, et al.
Publicado: (2020)

LGG-44. PROGNOSTIC SIGNIFICANCE OF IMAGING CHARACTERISTICS IN PEDIATRIC LOW GRADE GLIOMAS
por: Baig, Muhammad, et al.
Publicado: (2020)

LGG-06. LONG-TERM OUTCOME OF NEWLY DIAGNOSED LOW GRADE GLIOMA
por: Sirachainan, Nongnuch, et al.
Publicado: (2020)

LGG-10. AN UNUSUAL PRESENTATION OF BILATERAL OPTIC NERVE GLIOMA IN CROUZON SYNDROME
por: Na, Brian, et al.
Publicado: (2021)

LGG-02. PEDIATRIC LOW-GRADE GLIOMA RISK STRATIFICATION IN THE MOLECULAR ERA
por: Hata, Jessica, et al.
Publicado: (2021)

LGG-20. CLINICAL FEATURES AND TREATMENT RESULTS FOR PEDIATRIC OPTICO-HYPOTHALAMIC ASTROCYTOMA
por: Yoshimoto, Koji, et al.
Publicado: (2020)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas
por: Lindsay, Holly, et al.
Publicado: (2022)

LGG-59. Identifying hidden drivers of low-grade glioma tumor growth
por: Misek, Sean, et al.
Publicado: (2022)

LGG-03. Pediatric spinal deformities concomitant with spinal cord pilocytic astrocytoma
por: Kapitancuke, Monika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_or6ftueo1ll6t9gufom8gvakqp